First-line therapy with metronomic capecitabine (mC) plus docetaxel (D) followed by mC as maintenance for patients with HER2-negative metastatic breast cancer (MBC): Preliminary analysis of a monocentric phase II trial / G. Aurilio, A.S.. - In: JOURNAL OF CLINICAL ONCOLOGY. - ISSN 0732-183X. - 29:15_suppl(2011). (ASCO Annual Meeting 2011) [10.1200/JCO.2011.29.15_SUPPL.E11547].
First-line therapy with metronomic capecitabine (mC) plus docetaxel (D) followed by mC as maintenance for patients with HER2-negative metastatic breast cancer (MBC): Preliminary analysis of a monocentric phase II trial
D. Radice;G. Curigliano;
2011
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
